Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations

Tenofovir alafenamide (TAF) is a phosphonoamidate prodrug of the nucleotide HIV reverse transcriptase inhibitor tenofovir (TFV). TAF is approved for the treatment of HIV-1 infection as part of the single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and TAF. When dosed once-dail...

Descripción completa

Detalles Bibliográficos
Autores principales: Callebaut, Christian, Liu, Yang, Babusis, Darius, Ray, Adrian, Miller, Michael, Kitrinos, Kathryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300148/
https://www.ncbi.nlm.nih.gov/pubmed/28182625
http://dx.doi.org/10.1371/journal.pone.0169948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300148/
https://www.ncbi.nlm.nih.gov/pubmed/28182625
http://dx.doi.org/10.1371/journal.pone.0169948

Ejemplares similares